338840
Y-Biologics, Inc., an antibody therapeutics development company, engages in the research and development of immuno-oncology drugs and antibody drugs. The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor. It also develops immunoregulatory monoclonal antibodies, such as YBL-011 and AR062 for the treatment of solid cancers; AR166,… Read more
338840 (338840) - Total Liabilities
Latest total liabilities as of March 2025: ₩3.17 Billion KRW
Based on the latest financial reports, 338840 (338840) has total liabilities worth ₩3.17 Billion KRW as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
338840 - Total Liabilities Trend (2022–2024)
This chart illustrates how 338840's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
338840 Competitors by Total Liabilities
The table below lists competitors of 338840 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NIIT LEARNING SYSTEMS LTD
NSE:NIITMTS
|
India | ₹12.34 Billion |
|
Circassia Group Plc
OTCGREY:CSSPF
|
USA | $6.60 Million |
|
Manorama Industries Limited
NSE:MANORAMA
|
India | ₹4.61 Billion |
|
Runben Biotechnology Co Ltd Ordinary Shares - Class A
SHG:603193
|
China | CN¥134.06 Million |
|
Tristel PLC
PINK:TSNLF
|
USA | $11.88 Million |
|
ADVA Optical Networking SE
PINK:ADVOF
|
USA | $270.47 Million |
|
389650
KQ:389650
|
Korea | ₩11.84 Billion |
|
Heba Fastighets AB Series B
LSE:0GNV
|
UK | Skr8.00 Billion |
Liability Composition Analysis (2022–2024)
This chart breaks down 338840's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 3.21 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 338840's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 338840 (2022–2024)
The table below shows the annual total liabilities of 338840 from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩3.37 Billion | -51.04% |
| 2023-12-31 | ₩6.89 Billion | -59.57% |
| 2022-12-31 | ₩17.03 Billion | -- |